• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Vevye (cyclosporine ophthalmic solution) 0.1% is now commercially available in US

Press Release

Harrow’s Vevye is the first and only cyclosporine-based product approved for the treatment of both signs and symptoms of dry eye disease.

cyclosporine ophthalmic solution Vevye 0.1% from Harrow on the pharmacy counter - Image credit: Piman Khrutmuang - stock.adobe.com

Image credit: Piman Khrutmuang - stock.adobe.com

Harrow announced that Vevye (cyclosporine ophthalmic solution) 0.1% is now available for purchase in the United States and is backed by a 100% money-back guarantee program.1 Vevye, which was approved by the FDA in June 2023, is the first and only cyclosporine-based product indicated for the signs and symptoms of dry eye disease (DED). It is a non-preserved, water-free semifluorinated alkane eye drop that is to be instilled twice daily.

“We are thrilled to announce the availability of VEVYE for our customers and their patients,” Mark L. Baum, chairman and chief executive officer of Harrow, said in a press release. “VEVYE is powered by the unique combination of the reliable and trusted active ingredient, cyclosporine, and a water-free semifluorinated alkane delivery vehicle, perfluorobutylpentane. We are excited to see VEVYE’s exceptional clinical trial data come to life as U.S. dry eye disease patients are now able to access and experience a highly tolerable product that provides rapid onset of relief and sustained improvement of both signs and symptoms of dry eye disease. Because of VEVYE’s unique combination of both a potent 0.1% cyclosporine solute and a pH- and osmolarity-free semifluorinated alkane, VEVYE is both evolutionary and revolutionary, solving an unmet need for eyecare professionals treating the tens of millions of American chronic dry eye disease sufferers.”

Vevye cyclosporine ophthalmic solution 0.1% is now commercially available in the US

Image courtesy of Harrow

To order a prescription for Vevye, eye care professionals can leverage Harrow’s dedicated pharmacy partner, PhilRx, via an electronic medical record. Vevye is also fully stocked in the wholesale distribution channel, and stock can be shipped to any retail pharmacy. Shipping typically takes place within 24 hours of the order. Stock is also available via wholesale distributors McKesson, Cardinal, and Cencora.1

Harrow’s 100% money-back guarantee program is only available for eligible patients, who must pay cash and do not have commercial or government insurance, including (but not limited to) Medicare or Medicaid. The offer is also only available for one fill only. The money-back guarantee is available through any participating retail pharmacy, and questions regarding application can be answered by calling (833) 442-7769.1

Harrow announces availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the first and only cyclosporine-based product indicated for treating both signs and symptoms of dry eye disease. Press release. Published January 11, 2024. Accessed January 11, 2024. https://www.biospace.com/article/releases/harrow-announces-availability-of-vevye-cyclosporine-ophthalmic-solution-0-1-percent-the-first-and-only-cyclosporine-based-product-indicated-for-treating-both-signs-and-symptoms-of-dry-eye-disease/
Related Videos
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Megan Cavet, PhD
Andrew Pucker, OD, PhD
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
Jessica Steen, OD, FAAO, discusses systemic medication and ocular adverse effects at Vision Expo East 2024
At Vision Expo East 2024, Srinivas Kondapalli, MD, demonstrates how to use Rinsada to address ocular surface disease.
Brujic at Rinsada Booth at Vision Expo East 2024
Marc R Bloomenstein, OD, FAAO, chats with Optometry Times about the benefits of Vevye in the treatment of dry eye
© 2024 MJH Life Sciences

All rights reserved.